Vivos Therapeutics (VVOS) Non-Current Receivables (2019 - 2021)

Vivos Therapeutics (VVOS) has 3 years of Non-Current Receivables data on file, last reported at $842290.0 in Q3 2021.

• Quarterly Non-Current Receivables changed N/A year-over-year to $842290.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $842290.0 (changed N/A YoY) and the FY2020 annual result came in at $811000.0, up 3.3% from the prior year.
• Non-Current Receivables held at $842290.0 in Q3 2021 per VVOS's latest filing, from $846214.0 in the prior quarter.
• Across five years, Non-Current Receivables topped out at $846214.0 in Q2 2021 and bottomed at $785061.0 in Q4 2019.
• The 3-year median for Non-Current Receivables is $816584.0 (2021), against an average of $820229.8.
• Peak annual rise in Non-Current Receivables reached 3.3% in 2020, while the deepest fall reached 3.3% in 2020.
• Tracing VVOS's Non-Current Receivables over 3 years: stood at $785061.0 in 2019, then increased by 3.3% to $811000.0 in 2020, then grew by 3.86% to $842290.0 in 2021.
• Per Business Quant, the three latest VVOS Non-Current Receivables figures stand at $842290.0 (Q3 2021), $846214.0 (Q2 2021), and $816584.0 (Q1 2021).

Peer Comparison